Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
- PMID: 11875500
- DOI: 10.1038/nm0302-282
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Abstract
The tumor suppressor p53 inhibits tumor growth primarily through its ability to induce apoptosis. Mutations in p53 occur in at least 50% of human tumors. We hypothesized that reactivation of mutant p53 in such tumors should trigger massive apoptosis and eliminate the tumor cells. To test this, we screened a library of low-molecular-weight compounds in order to identify compounds that can restore wild-type function to mutant p53. We found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53. This molecule, named PRIMA-1, restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells. PRIMA-1 rescued both DNA contact and structural p53 mutants. In vivo studies in mice revealed an antitumor effect with no apparent toxicity. This molecule may serve as a lead compound for the development of anticancer drugs targeting mutant p53.
Similar articles
-
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.Cell Oncol. 2008;30(5):411-8. doi: 10.3233/clo-2008-0440. Cell Oncol. 2008. PMID: 18791272 Free PMC article.
-
Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.Endocr Relat Cancer. 2009 Mar;16(1):85-98. doi: 10.1677/ERC-08-0069. Epub 2008 Dec 15. Endocr Relat Cancer. 2009. PMID: 19075036
-
Restoration of p53 to limit tumor growth.Curr Opin Oncol. 2008 Jan;20(1):90-6. doi: 10.1097/CCO.0b013e3282f31d6f. Curr Opin Oncol. 2008. PMID: 18043262 Review.
-
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Int J Oncol. 2009 Nov;35(5):1015-23. doi: 10.3892/ijo_00000416. Int J Oncol. 2009. PMID: 19787255
-
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.Oncogene. 2010 Jul 29;29(30):4245-52. doi: 10.1038/onc.2010.188. Epub 2010 May 24. Oncogene. 2010. PMID: 20498645 Review.
Cited by
-
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.J Biomed Sci. 2020 Jul 21;27(1):81. doi: 10.1186/s12929-020-00674-7. J Biomed Sci. 2020. PMID: 32690020 Free PMC article. Review.
-
Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.BMC Cancer. 2020 Jul 2;20(1):617. doi: 10.1186/s12885-020-07062-2. BMC Cancer. 2020. PMID: 32615946 Free PMC article.
-
Targeting p53 by small molecules in hematological malignancies.J Hematol Oncol. 2013 Mar 27;6:23. doi: 10.1186/1756-8722-6-23. J Hematol Oncol. 2013. PMID: 23531342 Free PMC article. Review.
-
Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction.Sci Adv. 2022 Sep 16;8(37):eabm9427. doi: 10.1126/sciadv.abm9427. Epub 2022 Sep 14. Sci Adv. 2022. PMID: 36103522 Free PMC article.
-
New Treatment Options for Older Patients with Acute Myeloid Leukemia.Curr Treat Options Oncol. 2021 Mar 20;22(5):39. doi: 10.1007/s11864-021-00841-4. Curr Treat Options Oncol. 2021. PMID: 33743079 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous